why choose us

First received: June 07, 2023

Clinical Trial: AMT-253 in Patients With Selected Advanced Solid Tumours

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors

Brief Summary: This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

Read more